Sparsentan after approval: Defining the treatment boundary in FSGS without nephrotic syndrome. // Nefrología. – URL: https://www.sciencedirect.com/science/article/pii/S021169952600113X?dgcid=rss_sd_all
Sparsentan after approval: Defining the treatment boundary in FSGS without nephrotic syndrome. Nefrología. https://www.sciencedirect.com/science/article/pii/S021169952600113X?dgcid=rss_sd_all
“Sparsentan after approval: Defining the treatment boundary in FSGS without nephrotic syndrome.” Nefrología.
@article{article94822,
title = {Sparsentan after approval: Defining the treatment boundary in FSGS without nephrotic syndrome},
journal = {Nefrología},
url = {https://www.sciencedirect.com/science/article/pii/S021169952600113X?dgcid=rss_sd_all}
}